Challenges and Outcomes of the First Stem Cell Transplant Program in Tanzania, East Africa.

Q3 Medicine
Advances in Hematology Pub Date : 2024-03-16 eCollection Date: 2024-01-01 DOI:10.1155/2024/1937419
Stella Rwezaula, Mbonea Yonazi, Amey Panchal, Ashish Dhoot, Jemy Mathew, Sonu Tony, Sandeep Rao, Peter Muhoka, Samira Mahfudh, Neema Budodi, Mabula Kasubi, Flora Ndobho, Helena Kakumbula, Koga Luhulla, Linda Kapesa, Heri Tungaraza, Sarah Nyagabona, Agnes Shayo, Felister Seleki, Janeth Mtenga, Khadija Mwamtemi, Musa Suko, Isaac Mbughi, Mariana Shirima, Alfayo Mkisi, Rahma Ally, Malselina Kyaruzi, Else Arola Myaka, Johari Matiku, Mariam Nyamwaira, Saranya Nair, Aswathy Asokan, Goutham Kumar, Raj Badavath, Hedwiga Swai, Lawrence Museru, B S Ajaikumar, Deogratius Beda, Sachin Jadhav
{"title":"Challenges and Outcomes of the First Stem Cell Transplant Program in Tanzania, East Africa.","authors":"Stella Rwezaula, Mbonea Yonazi, Amey Panchal, Ashish Dhoot, Jemy Mathew, Sonu Tony, Sandeep Rao, Peter Muhoka, Samira Mahfudh, Neema Budodi, Mabula Kasubi, Flora Ndobho, Helena Kakumbula, Koga Luhulla, Linda Kapesa, Heri Tungaraza, Sarah Nyagabona, Agnes Shayo, Felister Seleki, Janeth Mtenga, Khadija Mwamtemi, Musa Suko, Isaac Mbughi, Mariana Shirima, Alfayo Mkisi, Rahma Ally, Malselina Kyaruzi, Else Arola Myaka, Johari Matiku, Mariam Nyamwaira, Saranya Nair, Aswathy Asokan, Goutham Kumar, Raj Badavath, Hedwiga Swai, Lawrence Museru, B S Ajaikumar, Deogratius Beda, Sachin Jadhav","doi":"10.1155/2024/1937419","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Due to the significant resources involved in creating HSCT programs there is a significant disparity in the availability of this treatment modality between the developed and developing countries. This manuscript details the process and the outcomes of the first HSCT program in East Africa which was started at Muhimbili National Hospital (MNH) in Dar-es-Salaam, Tanzania.</p><p><strong>Materials and methods: </strong>Information and data were collected on the processes which had been implemented for starting the HSCT program at MNH. The details of the collaborations, training, infrastructure development, and acquisition of the biomedical equipment, as well as the actual process for HSCT, as well as the outcomes of treatment are described. <i>Observations</i>. The project has been detailed in 4 stages for ease of description: Stage 1: Preparatory work which was performed by the Government of Tanzania, as well as the administrators and clinicians from MNH (July 2017-September 2021). Stage 2: Exploratory gap analysis by the teams from MNH and International Haematology Consortium of HCG Hospital, India (HCG-IHC) in October 2021. Stage 3: Activities for closure of gaps (November 2021). Stage 4: Stem Cell Transplantation Camps (November 2021 to March 2022). 11 peripheral blood stem cell transplants were done in two camps, November 2021 (5 patients), and February 2022 (6 patients). 10 patients underwent autologous peripheral blood stem cell transplantation for multiple myeloma and 1 for lymphoma. The median duration of hospital stay was 19 ± 6 days. The median time for neutrophil engraftment, it was on 8.8 ± 0.8 days, and for platelet engraftment was 9.6 ± 2.4 days. Progression-free survival was 100%, and there was no mortality.</p><p><strong>Conclusion: </strong>Commonalities in the socioeconomic challenges in developing countries can be leveraged to create robust HSCT programs in other developing countries.</p>","PeriodicalId":7325,"journal":{"name":"Advances in Hematology","volume":"2024 ","pages":"1937419"},"PeriodicalIF":0.0000,"publicationDate":"2024-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10960647/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in Hematology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2024/1937419","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Due to the significant resources involved in creating HSCT programs there is a significant disparity in the availability of this treatment modality between the developed and developing countries. This manuscript details the process and the outcomes of the first HSCT program in East Africa which was started at Muhimbili National Hospital (MNH) in Dar-es-Salaam, Tanzania.

Materials and methods: Information and data were collected on the processes which had been implemented for starting the HSCT program at MNH. The details of the collaborations, training, infrastructure development, and acquisition of the biomedical equipment, as well as the actual process for HSCT, as well as the outcomes of treatment are described. Observations. The project has been detailed in 4 stages for ease of description: Stage 1: Preparatory work which was performed by the Government of Tanzania, as well as the administrators and clinicians from MNH (July 2017-September 2021). Stage 2: Exploratory gap analysis by the teams from MNH and International Haematology Consortium of HCG Hospital, India (HCG-IHC) in October 2021. Stage 3: Activities for closure of gaps (November 2021). Stage 4: Stem Cell Transplantation Camps (November 2021 to March 2022). 11 peripheral blood stem cell transplants were done in two camps, November 2021 (5 patients), and February 2022 (6 patients). 10 patients underwent autologous peripheral blood stem cell transplantation for multiple myeloma and 1 for lymphoma. The median duration of hospital stay was 19 ± 6 days. The median time for neutrophil engraftment, it was on 8.8 ± 0.8 days, and for platelet engraftment was 9.6 ± 2.4 days. Progression-free survival was 100%, and there was no mortality.

Conclusion: Commonalities in the socioeconomic challenges in developing countries can be leveraged to create robust HSCT programs in other developing countries.

东非坦桑尼亚首个干细胞移植项目的挑战与成果。
导言:由于建立造血干细胞移植项目需要大量资源,发达国家和发展中国家在提供这种治疗方式方面存在巨大差距。本手稿详细介绍了坦桑尼亚达累斯萨拉姆穆欣比利国立医院(MNH)启动东非首个造血干细胞移植项目的过程和成果:收集了有关 MNH 启动造血干细胞移植项目的过程的信息和数据。详细介绍了合作、培训、基础设施建设、生物医学设备购置、造血干细胞移植的实际过程以及治疗结果。意见。为便于描述,该项目分为四个阶段:第 1 阶段:坦桑尼亚政府以及 MNH 的管理人员和临床医生开展的准备工作(2017 年 7 月至 2021 年 9 月)。第 2 阶段:2021 年 10 月,由 MNH 和印度 HCG 医院国际血液学联合会(HCG-IHC)的团队进行探索性差距分析。第 3 阶段:弥补差距的活动(2021 年 11 月)。第 4 阶段:干细胞移植营(2021 年 11 月至 2022 年 3 月)。分别于 2021 年 11 月(5 名患者)和 2022 年 2 月(6 名患者)在两个营地进行了 11 例外周血干细胞移植。10名患者因多发性骨髓瘤接受了自体外周血干细胞移植,1名患者因淋巴瘤接受了自体外周血干细胞移植。中位住院时间为19±6天。中性粒细胞移植的中位时间为(8.8±0.8)天,血小板移植的中位时间为(9.6±2.4)天。无进展生存率为100%,无死亡病例:结论:发展中国家面临的社会经济挑战存在共性,可利用这些共性在其他发展中国家建立健全的造血干细胞移植项目。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Advances in Hematology
Advances in Hematology Medicine-Hematology
CiteScore
3.30
自引率
0.00%
发文量
10
审稿时长
15 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信